Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment Resistant Immunoglobulin Light Chain Amyloidosis with Multiple Myeloma

We report a relapsed and refractory Multiple Myeloma (RRMM) and AL Amyloidosis patient responding to elotuzumab/lenalidomide/dexamethasone (ERD). A 51-year-old woman presented with a right mandibular mass with positive Congo-red staining, clonal kappa free-light chains (κFLC) and plasma cell proliferation. Workup was consistent with κFLC amyloidosis and MM with nephrotic range proteinuria. After progression on several lines of therapy, she has near complete reversal of proteinuria while being maintained on ERD. This regimen should be tested in patients with AL Amyloidosis.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research